Protocol Ledger

NCT04540211 · Phase III · COMPLETED

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurr

Interventional Phase III clinical trial protocol NCT04540211 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-30 Enrollment: 461 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04540211
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)461 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04540211
Protocol FieldVerified Registry Value
NCT IdentifierNCT04540211
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment461 participants (ACTUAL)
Registered Start Date2020-10-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04540211
Hospital Research SiteLocationSite Profile
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Jilin Cancer HospitalChangchun, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
West China Hospital,Sichuan UniversityChengdu, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI